WallStSmart
CGON

CG Oncology, Inc. Common stock

NASDAQ: CGON · HEALTHCARE · BIOTECHNOLOGY

$64.75
-1.22% today

Updated 2026-04-29

Market cap
$5.70B
P/E ratio
P/S ratio
1,410.56x
EPS (TTM)
$-2.08
Dividend yield
52W range
$21 – $74
Volume
1.3M

CG Oncology, Inc. Common stock (CGON) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-13.2%
Last 4 quarters
Revenue YoY growth
+409.2%
Most recent quarter
EPS YoY growth
-10.9%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+1.2%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+9.2%
2025-11-14
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-27$-0.51-6.3%$66.67$63.96-4.1%
2025-11-14$-0.57-4.3%$37.76$41.25+9.2%
2025-08-08$-0.54-22.1%$24.35$23.95-1.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.48$-0.51-6.3%$2.32M+409.2%
2025-09-30$-0.55$-0.57-4.3%$1.67M+3774.4%
2025-06-30$-0.44$-0.54-22.1%
2025-03-31$-0.37$-0.45-20.3%$52000.00-90.2%
2024-12-31$-0.45$-0.46-2.2%$456000.00+45500.0%
2024-09-30$-0.42$-0.30+28.6%$43000.00
2024-06-30$-0.40$-0.28+30.0%$111000.00
2024-03-31$-0.29$-0.36-24.1%$529000.00
2023-12-31$-0.67$-0.33+50.6%$1000.00

Frequently asked questions

Has CG Oncology, Inc. Common stock beaten earnings estimates?
CG Oncology, Inc. Common stock has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -13.2% over the last 4 quarters.
How does CGON stock react to earnings?
CGON stock has moved an average of +1.2% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is CG Oncology, Inc. Common stock's revenue growth rate?
CG Oncology, Inc. Common stock reported year-over-year revenue growth of +409.2% in its most recent quarter, with EPS growing -10.9% year-over-year.